What We Do
PrimeGen has developed the stemXcell™ platform to streamline the discovery of key cytokines, proteins and other agents required to activate or prepare human umbilical cord-derived mesenchymal stem cells to treat targeted inflammatory diseases.
The stemXcell™ platform enables PrimeGen to:
Increase Potency – Deliver highly potent, allogeneic stem-cell therapies that are pre-activated to treat a specific disease.
Scalable Production – Achieve unprecedented scalability with the use of allogeneic human umbilical MSCs and proprietary cryoprotective methods. Human umbilical cord-derived stem cells can support multiple passages resulting in the production of billions of potent cells. PrimeGen’s proprietary cryoprotective methods allow for large-scale production, storage, and distribution of potent activated MSCs.
Deliver targeted therapies on a disease-by-disease basis.
Improved Efficacy – Enable the delivery of superior and patented cell therapy solutions into largely unserved markets.
Currently, PrimeGen US is focused on delivering activated therapies for multiple disease types in the $300+ billion market for treating liver disease in the US. Our stemXcell™ activation technology can be applied to most proven MSC-based therapies.
Our intent is to deliver a solution for acute and chronic liver disease and then to pursue and/or license stemXcell solutions for other inflammatory conditions, such as: diabetes, atherosclerosis, arthritis, as well as osteoarthritis and dermal wound healing.
There is a large opportunity for PrimeGen to apply its stemXcell activation and acceleration to already proven MSC therapies.
We begin by sourcing diseased tissue and blood from patients in order to identify up-regulated disease-specific biomarkers. Those biomarkers are used as potent factors for the activation of hUC-MSCs. Once activated, these cells are to be used for novel treatment of specific diseases.
2. Grow & Activate
In this step, hUC-MSCs are culture expanded and activated using the cytokines determined in the Discovery phase.
3. Test In-vitro
Our In-Vitro testing protocols utilize Multiplex ELISA assays to measure the cytokine secretion of our stemXcell activated hUC-MSCs. We use this data to select and further test the most effective activation factors for treating the disease.
4. Test In-Vivo
Our proprietary In-Vivo testing methodoligies utilize humanized mouse models for specific human disease indications. These tests are designed to examine the functional and therapeutic benefits of our cytokine-activated hUC-MSCs in treating specific diseases.
Finally, we analyze the data from both the in vitro and in vivo experiments to confirm that the activated hUC-MSCs produce the desired therapeutic effect on the humanized mouse disease model.
These results are used to further determine our activated MSC potency assay for later clinical use.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. PrimeGen US, Inc. makes no representation and assumes no responsibility for the accuracy of information contained on or available through this web site, and such information is subject to change without notice. You are encouraged to confirm any information obtained from or through this web site with other sources, and review all information regarding any medical condition or treatment with your physician.
NEVER DISREGARD PROFESSIONAL MEDICAL ADVICE OR DELAY SEEKING MEDICAL TREATMENT BECAUSE OF SOMETHING YOU HAVE READ ON OR ACCESSED THROUGH ANY WEB SITE.